Olmesartan
- Generic Name
- Olmesartan
- Brand Names
- Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N6O3
- CAS Number
- 144689-24-7
- Unique Ingredient Identifier
- 8W1IQP3U10
- Background
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 449
- Registration Number
- NCT00362115
Amlodipine as add-on to Olmesartan in Hypertension
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 429
- Registration Number
- NCT00220220
Olmesartan as an add-on to Amlodipine in Hypertension
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 632
- Registration Number
- NCT00220233
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT00185068
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT00185055
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1900
- Registration Number
- NCT00185133
Olmesartan in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-29
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 2333
- Registration Number
- NCT00185172
- Locations
- 🇨🇭
PFC Pharma Focus Consultants AG, Zurich, Volketswil, Switzerland
🇵🇹EUROTRIALS Lda, Lisboa, Portugal
🇳🇱IMRO TRAMARKO International bv, Berghem, Netherlands
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT00185094
Olmesartan Medoxomil in Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 4449
- Registration Number
- NCT00185159
Olmesartan Medoxomil in Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-12-14
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 165
- Registration Number
- NCT00185185
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.